Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8

specific

Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No d

16

Centers

19

Active Trials

Cancer Funding

Top Centers for Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8(16)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
171.4
2
NCI Comprehensive
High-Volume Research Center
71.4
3
High-Volume Research Center
71.4
4
NCI Comprehensive
Active Research Program
48.9
5
NCI Comprehensive
Active Research Program
48.9
6
NCI Comprehensive
Active Research Program
48.9
7
NCI Comprehensive
Active Research Program
48.9
8
NCI Comprehensive
Active Research Program
48.9
9
NCI Comprehensive
Active Research Program
48.9
10
Active Research Program
48.9
11
NCI Comprehensive
Active Research Program
48.9
12
NCI Clinical
Active Research Program
48.9
13
Active Research Program
48.9
14
Active Research Program
48.9
15
Active Research Program
48.9
16
Active Research Program
48.9

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →